Paris, France – DATE, 2016 - Seventure Partners, one of Europe’s leaders in financing innovation, today announces that for the second year running it is leading a panel at this year’s Bio-Europe conference, taking place 7-9 November in Cologne, Germany.
Chaired by Venture Partner Eric de La Fortelle, the session, entitled ‘Your Microbiome and Lifelong Health’ session will take place on Monday 7 November, 1.30-2.30 p.m. in Room 2, Level 2, as part of the Human Healthcycle Track. Eric will be joined by panelists Daniel Cuoto, VP, Process Development and Manufacturing, Vedanta Biosciences; and Gregory Lambert, CEO of TargEDys.
The panel will provide insights into the lifelong health impact of individuals’ microbiomes and discuss current research, bolstered by investment and large-scale research initiatives across the world. It will also focus on breakthroughs in the understanding of the human microbiome and breakthroughs in identification, diagnosis and potential treatment options in multiple disease areas, as well as how a shift towards awareness of the microbiome can contribute to lifelong health management.
Isabelle de Cremoux, President and Managing Partner of Seventure Partners, who will also attend the session, said: “We have seen a fast rise in the number of microbiome-focused companies seeking funding over the past few years. Academia and the life sciences industry are making great headway in translating discoveries in the microbiome into new healthcare approaches. Our Microbiome panel at Bio-Europe will seek to explore the key highlights of existing research, as well as potential investment opportunities in the market.”
About Seventure Partners
With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America.
In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.
Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
